Osteoporosis International

, Volume 21, Supplement 2, pp 403–406 | Cite as

Microarchitecture in focus



Disclosure statement

R.R. is a speaker for Amgen, Novartis, Danone, Merck, Roche, Servier, and is a member of the scientific advisory board of Amgen, Danone, Eli Lilly, Nycomed, Servier, Roche, Novartis.


  1. 1.
    Ammann P, Rizzoli R, Bonjour JP (1998) Preclinical evaluation of new therapeutic agents for osteoporosis. In: Meunier PJ (ed) Osteoporosis: diagnosis and management. Dunitz, London, pp 257–273Google Scholar
  2. 2.
    Rizzoli R, Bruyere O, Cannata-Andia JB, Devogelaer JP, Lyritis G, Ringe JD, Vellas B, Reginster JY (2009) Management of osteoporosis in the elderly. Curr Med Res Opin 25:2373–2387Google Scholar
  3. 3.
    Delmas PD, Seeman E (2004) Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with anti-resorptive therapy. Bone 34:599–604CrossRefPubMedGoogle Scholar
  4. 4.
    Russell RGG, Espina B, Hulley Ph (2006) Bone biology and the pathogenesis of osteoporosis. Curr Opin Rheumatol 18(1):S3–S11CrossRefPubMedGoogle Scholar
  5. 5.
    Kalpakcioglu BB, Morshed S, Engelke K, Genant HK (2008) Advanced imaging of bone macrostructure and microstructure in bone fragility and fracture repair. J Bone Joint Surg Am 90(Suppl 1):68–78CrossRefPubMedGoogle Scholar
  6. 6.
    Genant HK, Engelke K, Prevrhal S (2008) Advanced CT bone imaging in osteoporosis. Rheumatology (Oxford) 47(suppl 4):iv9–iv16CrossRefGoogle Scholar
  7. 7.
    Bouxsein ML (2009) Measuring bone quality and bone strength. In: Innovation in skeletal medicine. Elsevier-Masson, pp 85–98Google Scholar
  8. 8.
    Bouxsein ML (2008) Technology insight: noninvasive assessment of bone strength in osteoporosis. Nat Clin Pract Rheumatol 4(6):310–318CrossRefPubMedGoogle Scholar
  9. 9.
    Siris ES, Chen YT, Abbott TA et al (2004) Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med 164:1108–1112CrossRefPubMedGoogle Scholar
  10. 10.
    Schuit SC, van der Klift M, Weel AE et al (2004) Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam study. Bone 34:195–202CrossRefPubMedGoogle Scholar
  11. 11.
    Arlot ME, Jiang Y, Genant HK et al (2008) Histomorphometric and μCT analysis of bone biopsies from postmenopausal osteoporotic women treated with strontium ranelate. J Bone Miner Res 23:215–222CrossRefPubMedGoogle Scholar
  12. 12.
    Croucher PI, Garrahan NJ, Compston JE (1996) Assessment of cancellous bone structure: comparison of strut analysis, trabecular bone pattern factor and marrow space star volume. J Bone Miner Res 11:955–961CrossRefPubMedGoogle Scholar
  13. 13.
    Brandi ML (2009) Microarchitecture, the key to bone quality. Rheumatology 48:iv3–iv8CrossRefPubMedGoogle Scholar
  14. 14.
    Jårvinen TLN, Sievånen H, Jokihaara J, Einhorn TA (2005) Revival of bone strength: the bottom line. J Bone Miner Res 20:717–720CrossRefPubMedGoogle Scholar
  15. 15.
    Boutroy S, Bouxsein ML, Munoz F, Delmas PD (2005) In vivo assessment of trabecular bone microarchitecture by high-resolution peripheral quantitative computed tomography. J Clin Endocrinol Metab 90:6508–6515CrossRefPubMedGoogle Scholar
  16. 16.
    Khosla S, Riggs BL, Atkinson EJ, Oberg AL, McDaniel LJ, Holets M et al (2006) Effects of sex and age on bone microstructure at the ultradistal radius: a population-based noninvasive in vivo assessment. J Bone Miner Res 21:124–131CrossRefPubMedGoogle Scholar
  17. 17.
    Ettinger B, Black DM, Mitlak BH et al (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282:637–645CrossRefPubMedGoogle Scholar
  18. 18.
    Riggs BL, Melton LJ 3rd (2002) Bone turnover matters: the raloxifene treatment paradox of dramatic decreases in vertebral fractures without commensurate increases in bone density. J Bone Miner Res 17:11–14CrossRefPubMedGoogle Scholar
  19. 19.
    Hochberg MC, Greenspan S, Wasnich RD et al (2002) Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 87:1586–1592CrossRefPubMedGoogle Scholar
  20. 20.
    Liberman UA, Weiss SR, Bröll J, the Alendronate Phase III Osteoporosis Treatment Study Group et al (1995) N Engl J Med 333:1437–1443, Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosisCrossRefPubMedGoogle Scholar
  21. 21.
    Black DM, Cummings SR, Karpf DB et al (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535–1541CrossRefPubMedGoogle Scholar
  22. 22.
    Delmas PD, Bjarnason NH, Mitlak BH et al (1997) Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 337:1641–1647CrossRefPubMedGoogle Scholar
  23. 23.
    Cummings SR, Karpf DB, Harris F et al (2002) Improvement in Spine Bone Density and reduction in risk of vertebral fractures during treatment antiresorptive drugs. Am J Med 112(4):281–289CrossRefPubMedGoogle Scholar
  24. 24.
    Ammann P, Rizzoli R, Meyer JM et al (1996) Bone density and shape as determinants of bone strength in IGF-I and/or pamidronate-treated ovariectomized rats. Osteoporos Int 6:219–227CrossRefPubMedGoogle Scholar
  25. 25.
    Balena R, Toolan BC, Shea M et al (1993) The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primate. J Clin Invest 92:2577–86CrossRefPubMedGoogle Scholar
  26. 26.
    Blake GM, Lewiecki EM, Kendler DL, Fogelman I (2007) A review of strontium ranelate and its effect on DXA scans. J Clin Densitom 10:113–119CrossRefPubMedGoogle Scholar
  27. 27.
    Blake GM, Fogelman I (2007) The correction of BMD measurements for bone strontium content. J Clin Densitom 10:259–265CrossRefPubMedGoogle Scholar
  28. 28.
    Bruyere O, Roux C, Detilleux J et al (2007) Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate. J Clin Endocrinol Metab 92:3076–3081CrossRefPubMedGoogle Scholar
  29. 29.
    Bruyère O, Roux C, Badurski J et al (2007) Relationship between change in femoral neck bone mineral density and hip fracture incidence during treatment with strontium ranelate. Curr Med Res Opin 23:3041–3045CrossRefPubMedGoogle Scholar
  30. 30.
    Rizzoli R, Felsenberg D, Laroche M et al (2009) Superiority of strontium ranelate as compared to alendronate on microstructural determinants of bone strength at the distal tibia in women with postmenopausal osteoporosis. Ann Rheum Dis 68:669Google Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2010

Authors and Affiliations

  1. 1.Division of Bone Diseases, Department of Rehabilitation and GeriatricsGeneva University Hospitals and Faculty of MedicineGeneva 14Switzerland

Personalised recommendations